Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces a new article from Germany in the well-respected Journal of Laparoendoscopic & Advanced Surgical Techniques (https://pubmed.ncbi.nlm.nih.gov/40152889/) showing excellent RefluxStop™ results in a real-world setting, akin to those achieved in the CE mark study.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that RefluxStop™ attracted significant attention and discussion at the Society of American Gastrointestinal Endoscopic Surgeons (SAGES) Annual Meeting earlier this month in Long Beach, California.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that the RefluxStop™ procedure is now being performed at the Hospital Vithas 9 de Octubre, in Valencia, Spain.

RefluxStop™ FDA Milestone

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that U.S. FDA has completed its review of the PMA Module 2 submission and provided its feedback, in which the company sees no barrier for responding.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, is pleased to announce that the FDA has accepted Module 1 of the company’s premarket approval (PMA) application, and that this module is now considered closed.

Implantica AG (publ) invites investors to a presentation of the Year-end Report (Q4 2024) at 15:00 CET on February 14. The Year-end Report (Q4 2024) will be published at 8:00 a.m. CET on the same day.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces onboarding of the 12[th] Center of Excellence in Spain, the La Paz University Hospital in Madrid, one of the most prestigious and world-leading hospitals.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, reports that a leading pioneer of innovation healthcare services in the NHS England, NHS Chelsea & Westminster Hospital, hosted the first Gastrointestinal experts focused RefluxStop™ educational meeting in January 2025.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the journal Surgery Open Science, affiliated with the prestigious journal Surgery, recently published the largest real-world study from Germany, “A retrospective study assessing RefluxStop surgery for gastroesophageal reflux disease: Clinical outcomes in 79 patients from Germany (https://www.sciencedirect.com/science/article/pii/S2589845024001398)”.